Blood markers of oxidative stress in Alzheimer's disease

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 10, 2012, Pages 2291-2300

  Skoumalová, Alice ^a   Hort, Jakub ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Alzheimer disease; Blood markers; Lipid peroxidation; Oxidative stress

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; NUCLEIC ACID; PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD; BRAIN; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; ANTIOXIDANTS; BIOLOGICAL MARKERS; BRAIN; HUMANS; LIPID PEROXIDATION; NUCLEIC ACIDS; OXIDATIVE STRESS; PROTEINS;

EID: 84866755946     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2012.01585.x     Document Type: Article

References (89)

1. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34: 939-44.
2. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007; 22: 2314-24.
3. Alberts MJ, Latchaw RE, Jagoda A, et al. Revised and updated recommendations for the establishment of primary stroke centers: a summary statement from the brain attack coalition. Stroke. 2011; 42: 2651-65.
4. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011; 7: 263-9.
5. Hort J, O'Brien JT, Gainotti G, et al. On Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010; 17: 1236-48.
6. Hort J, Glosová L, Vyhnálek M, et al. The liquor tau protein and beta amyloid in Alzheimer's disease. Ces Slov Neurol Neurochir. 2007; 70: 30-6.
7. Maruta C, Guerreiro M, de Mendonça A, et al. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol. 2011; 18: 279-85.
8. Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging. 2011; 32: 20-36.
9. Teunissen CE, de Vente J, Steinbusch HW, De Bruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging. 2002; 23: 485-508.
10. Blennow K. Biomarkers in Alzheimer's disease drug development. Nat Med. 2010; 16: 1218-22.
11. Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010; 59: 290-4.
12. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis. Neurobiol Aging. 2009; 30: 337-52.
13. Popescu BO, Toescu EC, Popescu LM, et al. Blood-brain barrier alterations in ageing and dementia. J Neurol Sci. 2009; 283: 99-106.
14. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011; 17: 1060-5.
15. Shimohama S, Tanino H, Kawakami N, et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun. 2000; 273: 5-9.
16. Cagnin A, Brooks DJ, Kennedy AM, et al. In vivo measurement of activated microglia in dementia. Lancet. 2001; 358: 461-7.
17. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's β-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000; 130: 184-208.
18. Lynch T, Herny RA, Bush AI. Oxidative processes in Alzheimer's disease: the role of Aβ-metal interactions. Exp Gerontol. 2000; 35: 445-51.
19. Cornet CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicity. 1998; 19: 339-45.
20. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001; 60: 759-67.
21. Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol. 2000; 59: 1011-7.
22. Odetti P, Angelini G, Dapino D, et al. Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun. 1998; 243: 849-51.
23. Pratico D, Uryu K, Leight S, et al. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci. 2001; 21: 4183-7.
24. Söderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer disease. Lipids. 1991; 26: 421-5.
25. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995; 45: 1594-601.
26. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998; 19: 33-6.
27. Keller JN, Schmitt FA, Scheff SW, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology. 2005; 7: 1152-6.
28. Butterfield DA, Reed T, Perluigi M, et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett. 2006; 3: 170-3.
29. Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007; 33: 114-9.
30. Praticò D, Clark CM, Lee VM, et al. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol. 2000; 48: 809-12.
31. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ II. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann Neurol. 1998; 44: 410-3.
32. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol. 2005; 5: 730-5.
33. Roberts LJ II, Montine TJ, Markesbery WR, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem. 1998; 273: 13605-12.
34. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: cross-sectional study. Croat Med J. 2002; 43: 28-32.
35. Polidori MC, Mecocci P. Plasma susceptibility to free radical-induced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J Alzheimers Dis. 2002; 4: 517-22.
36. Aybek H, Ercan F, Aslan D, Sahiner T. Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey. Clin Biochem. 2007; 40: 172-6.
37. Bourdel-Marchasson I, Delmas-Beauvieux MC, Peuchant E, et al. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing. 2001; 30: 235-41.
38. Greilberger J, Koidl C, Greilberger M, et al. Malondialdehyde, carbonyl proteins and albumin-disulphide as useful oxidative markers in mild cognitive impairment and Alzheimer's disease. Free Radic Res. 2008; 42: 633-8.
39. Casado A, Encarnación López-Fernández M, Concepción Casado M, de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res. 2008; 33: 450-8.
40. Martín-Aragón S, Bermejo-Bescós P, Benedí J, et al. Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease. Neurochem Res. 2009; 34: 373-8.
41. Cecchi C, Fiorillo C, Sorbi S, et al. Oxidative stress and reduced antioxidant defenses in peripheral cells from familial Alzheimer's patients. Free Radic Biol Med. 2002; 15: 1372-9.
42. Sinem F, Dildar K, Gökhan E, et al. The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy. Curr Alzheimer Res. 2010; 7: 463-9.
43. Serra JA, Domínguez RO, Marschoff ER, et al. Systemic oxidative stress associated with the neurological diseases of aging. Neurochem Res. 2009; 34: 2122-32.
44. Serra JA, Domínguez RO, de Lustig ES, et al. Parkinson's disease is associated with oxidative stress: comparison of peripheral antioxidant profiles in living Parkinson's, Alzheimer's and vascular dementia patients. J Neural Transm. 2001; 108: 1135-48.
45. Kawamoto EM, Munhoz CD, Glezer I, et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer's disease. Neurobiol Aging. 2005; 26: 857-64.
46. Ahlskog JE, Uitti RJ, Low PA, et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease. Mov Disord. 1995; 10: 566-73.
47. Ceballos-Picot I, Merad-Boudia M, Nicole A, et al. Peripheral antioxidant enzyme activities and selenium in elderly subjects and in dementia of Alzheimer's type-place of the extracellular glutathione peroxidase. Free Radic Biol Med. 1996; 20: 579-87.
48. Fernandes MA, Proenca MT, Nogueira AJ, et al. Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med. 1999; 4: 179-86.
49. Sinclair AJ, Bayer AJ, Johnston J, et al. Altered plasma antioxidant status in subjects with Alzheimer's disease and vascular dementia. Int J Geriatr Psychiatry. 1998; 13: 840-5.
50. McGrath LT, McGleenon BM, Brennan S, et al. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM. 2001; 94: 485-90.
51. Polidori MC, Mattioli P, Aldred S, et al. Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. Dement Geriatr Cogn Disord. 2004; 18: 265-70.
52. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging. 2002; 23: 383-8.
53. Calabrese V, Sultana R, Scapagnini G, et al. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal. 2006; 8: 1975-86.
54. Praticò D, Clark CM, Liun F, et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002; 59: 972-6.
55. Irizarry MC, Yao Y, Hyman BT, et al. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis. 2007; 4: 403-5.
56. Feillet-Coudray C, Tourtauchaux R, Niculescu M, et al. Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med. 1999; 27: 463-9.
57. Montine TJ, Quinn JF, Milatovic D, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002; 52: 175-9.
58. Sundelöf J, Kilander L, Helmersson J, et al. Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis. 2009; 18: 71-8.
59. Hensley K, Hall N, Subramaniam R, et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem. 1995; 65: 2146-56.
60. Ahmed N, Ahmed U, Thornalley PJ, et al. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem. 2005; 92: 255-63.
61. Butterfield DA, Reed TT, Perluigi M, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 2007; 1148: 243-8.
62. Greilberger J, Fuchs D, Leblhuber F, et al. Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clin Lab. 2010; 56: 441-8.
63. Bermejo P, Martín-Aragón S, Benedí J, et al. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic Res. 2008; 42: 162-70.
64. Conrad CC, Marshall PL, Talent JM, et al. Oxidized proteins in Alzheimer's plasma. Biochem Biophys Res Commun. 2000; 275: 678-81.
65. Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer's disease. Clin Biochem. 2010; 43: 267-71.
66. Yu HL, Chertkow HM, Bergman H, Schipper HM. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics. 2003; 3: 2240-8.
67. Choi J, Malakowsky CA, Talent JM, et al. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem Biophys Res Commun. 2002; 293: 1566-70.
68. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol. 1994; 36: 747-51.
69. Nunomura A, Perry G, Pappolla MA, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci. 1999; 19: 1959-64.
70. Mullaart E, Boerrigter ME, Ravid R, et al. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging. 1990; 11: 169-73.
71. Mecocci P, Polidori MC, Ingegni T, et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology. 1998; 51: 1014-7.
72. Mecocci P, Polidori MC, Cherubini A, et al. Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol. 2002; 59: 794-8.
73. Mórocz M, Kálmán J, Juhász A, et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol Aging. 2002; 23: 47-53.
74. Kadioglu E, Sardas S, Aslan S, et al. Detection of oxidative DNA damage in lymphocytes of patients with Alzheimer's disease. Biomarkers. 2004; 9: 203-9.
75. Migliore L, Fontana I, Trippi F, et al. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol Aging. 2005; 26: 567-73.
76. Abe T, Tohgi H, Isobe C, et al. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J Neurosci Res. 2002; 70: 447-50.
77. Foy CJ, Passmore AP, Vahidassr MD, et al. Plasma chain-breaking antioxidants in Alzheimer's disease, vascular dementia and Parkinson's disease. QJM. 1999; 92: 39-45.
78. Jeandel C, Nicolas MB, Dubois F, et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology. 1989; 35: 275-82.
79. Rivière S, Birlouez-Aragon I, Nourhashémi F, Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry. 1998; 13: 749-54.
80. Zaman Z, Roche S, Fielde P, et al. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing. 1992; 21: 91-4.
81. Jiménez-Jiménez FJ, de Bustos F, Molina JA, et al. Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm. 1997; 104: 703-10.
82. Paraskevas GP, Kapaki E, Libitaki G, et al. Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand. 1997; 96: 88-90.
83. Repetto MG, Reides CG, Evelson P, et al. Peripheral markers of oxidative stress in probable Alzheimer patients. Eur J Clin Invest. 1999; 29: 643-9.
84. Guidi I, Galimberti D, Lonati S, et al. Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2006; 27: 262-9.
85. Grünblatt E, Schlösser R, Fischer P, et al. Oxidative stress related markers in the "VITA" and the centenarian projects. Neurobiol Aging. 2005; 26: 429-38.
86. Long EK, Picklo MJ Sr. Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic Biol Med. 2010; 49: 1-8.
87. Wilhelm J, Brzak P, Rejholcova M. Changes of lipofuscin-like pigments in erythrocytes and spleen after whole-body gamma irradiation of rats. Radiat Res. 1989; 120: 227-33.
88. Skoumalová A, Rofina J, Schwippelová Z, et al. The role of free radicals in canine counterpart of senile dementia of the Alzheimer type. Exp Gerontol. 2003; 38: 711-9.
89. Skoumalová A, Ivica J, Šantorová P, et al. The lipid peroxidation products as possible markers of Alzheimer's disease in blood. Exp Gerontol. 2011; 46: 38-42.